Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration

Daniel Woronow; Christine Chamberlain; Ali Niak; Mark Avigan; Monika Houstoun; Cindy Kortepeter

doi:10.1001/jamainternmed.2022.3810

Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration

JAMA Intern Med. 2022 Oct 1;182(10):1104-1106. doi: 10.1001/jamainternmed.2022.3810.

Authors

Daniel Woronow¹, Christine Chamberlain¹, Ali Niak¹, Mark Avigan², Monika Houstoun³, Cindy Kortepeter¹

Affiliations

¹ Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, Division of Pharmacovigilance, US Food and Drug Administration, Silver Spring, Maryland.
² Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, US Food and Drug Administration, Silver Spring, Maryland.
³ Center for Drug Evaluation and Research, Office of New Drugs, Division of Diabetes, Lipid Disorders, and Obesity, US Food and Drug Administration, Silver Spring, Maryland.

No abstract available

Plain language summary

This case series identifies cases reported in the US Food and Drug Administration Adverse Event Reporting System of acute cholecystitis associated with use of glucagon-like peptide-1 receptor agonists that did not have gallbladder disease warnings in their labeling.

MeSH terms

Cholecystitis, Acute*
Diabetes Mellitus, Type 2*
Glucagon-Like Peptide 1 / agonists
Glucagon-Like Peptide-1 Receptor / agonists
Humans
Hypoglycemic Agents / adverse effects
United States
United States Food and Drug Administration

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Glucagon-Like Peptide 1